Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens by Rickli, Anna et al.
  1 
Author version 
Receptor interaction profiles of novel psychoactive tryptamines compared with 
classic hallucinogens 
 
Anna Rickli,1 Olivier D. Moning,1 Marius C. Hoener,2 and Matthias E. Liechti1, * 
 
1Psychopharmacology Research, Division of Clinical Pharmacology and Toxicology, 
Department of Biomedicine, University Hospital Basel and University of Basel, Basel, 
Switzerland; 2Neuroscience Research, pRED, Roche Innovation Center Basel, F. 
Hoffmann-La Roche Ltd, Basel, Switzerland 
 
*Corresponding author: Prof. Dr. med. Matthias E. Liechti, Division of Clinical 
Pharmacology and Toxicology, University Hospital Basel, Hebelstrasse 2, Basel, CH-
4031, Switzerland. Tel: +41 61 328 68 68; Fax: +41 61 265 45 60; E-mail: 
matthias.liechti@usb.ch (M.E. Liechti) 
Word count: Manuscript 4914: Abstract: 180, References: 78, Tables: 3, Figures: 2 
 
Running title: Novel tryptamines 
  
  2 
Abstract  
The present study investigated interactions between the novel psychoactive 
tryptamines DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT at 
monoamine receptors and transporters compared with the classic hallucinogens 
lysergic acid diethylamide (LSD), psilocin, N,N-dimethyltryptamine (DMT), and 
mescaline. We investigated binding affinities at human monoamine receptors and 
determined functional serotonin (5-hydroxytryptamine [5-HT]) 5-HT2A and 5-HT2B 
receptor activation. Binding at and the inhibition of human monoamine uptake 
transporters and transporter-mediated monoamine release were also determined. All 
of the novel tryptamines interacted with 5-HT2A receptors and were partial or full 5-
HT2A agonists. Binding affinity to the 5-HT2A receptor was lower for all of the 
tryptamines, including psilocin and DMT, compared with LSD and correlated with the 
reported psychoactive doses in humans. Several tryptamines, including psilocin, 
DMT, DiPT, 4-OH-DiPT, and 4-OH-MET, interacted with the serotonin transporter 
and partially the norepinephrine transporter, similar to 3,4-
methylenedioxymethamphetamine but in contrast to LSD and mescaline. LSD but not 
the tryptamines interacted with adrenergic and dopaminergic receptors. In 
conclusion, the receptor interaction profiles of the tryptamines predict hallucinogenic 
effects that are similar to classic serotonergic hallucinogens but also MDMA-like 
psychoactive properties. 
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1. Introduction 
Classic or serotonergic hallucinogens can be grouped into different chemical 
groups, including tryptamines (e.g., psilocin and N,N-dimethyltryptamine [DMT]), 
ergolines (lysergic acid diethylamide [LSD]), and phenethylamines (e.g., mescaline). 
Psychoactive tryptamines are naturally found in toads, plants, and mushrooms. 
However, many synthetic tryptamine derivatives have been synthesized and are 
recreationally used as novel psychoactive substances (Araujo et al., 2015; EMCDDA, 
2014; Helander et al., 2014; Kamour et al., 2014; Shulgin and Shulgin, 1997; Tittarelli 
et al., 2015; Winstock et al., 2014). Tryptamines share their core structure with the 
neurotransmitter serotonin (5-hydroxytryptamine [5-HT]). The psychoactive effects of 
hallucinogens, including those of tryptamines, are thought to be mediated mainly by 
the 5-HT2A receptor (Glennon et al., 1984; Nichols, 2004; Titeler et al., 1988; 
Vollenweider et al., 1998) but may also be modulated by interactions with other 
targets, including other 5-HT receptors, monoamine transporters, and trace amine-
associated receptors (Baumeister et al., 2014; Bunzow et al., 2001; Cozzi et al., 
2009; Fantegrossi et al., 2006; McKenna et al., 1990; Nagai et al., 2007; Nichols, 
2004; Ray, 2010). Structural alterations of tryptamines have been shown to result in 
different pharmacological and psychoactive profiles (Araujo et al., 2015; McKenna et 
al., 1990; Repke et al., 1985; Shulgin and Shulgin, 1997; Tittarelli et al., 2015; 
Trachsel et al., 2013). For example, compounds that have no substitutions or a 4-
hydroxyl group (e.g., DMT or psilocin, respectively; Fig. 1) produce hallucinogenic 
effects with relative low potency in man (Repke et al., 1985). Psilocin is orally 
psychoactive above 5-10 mg, and DMT is active at parenteral doses of 20-100 mg 
(Araujo et al., 2015; Shulgin and Shulgin, 1997; Strassman et al., 1994; Studerus et 
al., 2011; Tittarelli et al., 2015). In contrast, a 5-methoxy group, such as in 5-MeO-
AMT (Fig. 1), resulted in greater compound potency, with subjective effects at 1-5 mg 
doses, more stimulant-type activation, and less visual perceptual alterations (Repke 
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et al., 1985). Different N-substitutions also influenced in vivo potency (Nichols et al., 
2015; Repke et al., 1985). The pharmacological profiles of many tryptamines have 
been studied previously at selected targets (Blough et al., 2014; Gatch et al., 2011; 
McKenna et al., 1990; Nichols et al., 2015; Repke et al., 1985; Shulgin and Carter, 
1980), and new and pharmacologically unknown tryptamine derivatives are 
constantly emerging on the illicit drug market (Araujo et al., 2015; Corkery et al., 
2012; EMCDDA, 2014; Greene, 2013; Helander et al., 2014; Tittarelli et al., 2015). 
Because small changes in molecular structure can alter the pharmacology of these 
novel designer drugs, studying the in vitro receptor interaction profiles of these novel 
substances is important. Such data can help predict psychotropic effects and acute 
clinical toxicity. Therefore, we assessed the receptor interaction profiles of a series of 
classic and novel tryptamines at human monoamine receptors and assessed 5-HT2A 
receptor activation. LSD and mescaline were included for comparison. Tryptamines 
have also been shown to interact with membrane monoamine transporters to inhibit 
their function or release monoamines through the transporter (Araujo et al., 2015; 
Cozzi et al., 2009; Nagai et al., 2007), similar to 3,4-
methylenedioxymethamphetamine (MDMA) and many other novel psychoactive 
substances (Rickli et al., 2015a; Simmler et al., 2013; Simmler et al., 2014a; Simmler 
et al., 2014b). Therefore, inhibition of the norepinephrine (NE), dopamine (DA), and 
5-HT transporters (NET, DAT, and SERT, respectively) and the release of NE, DA, 
and 5-HT were also investigated. MDMA was included as a comparator in these 
assays. 
The present study included recreationally used tryptamines (Araujo et al., 2015; 
EMCDDA, 2014; Greene, 2013; Schmidt et al., 2011; Tittarelli et al., 2015), including 
N,N-diisopropyltryptamine (DiPT), 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 
4-hydroxy-N-methyl-N-ethyltryptamine (4-OH-MET), 5-methoxy-α-methyltryptamine 
(5-MeO-AMT), and 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT; Fig. 
1). DiPT is a ring-unsubstituted tryptamine, similar to DMT. DiPT fully substituted for 
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DMT in discrimination studies (Gatch et al., 2011) but unlike DMT reportedly induces 
auditory and not visual alterations in humans (Blough et al., 2014). DiPT is 
psychoactive at doses of 20-100 mg, with effects that last 4-8 h (Shulgin and Carter, 
1980; Tittarelli et al., 2015). 
DiPT is an agonist at rat and human 5-HT2A receptors and also blocks the rat 
and human SERT (Blough et al., 2014; Cozzi et al., 2009; Gatch et al., 2011; Nagai 
et al., 2007). However, interactions with other receptors have not yet been studied.  
4-OH-DiPT has been detected in the urine of substance users (Pichini et al., 
2008), and a series of 4-OH-MET intoxications has recently been reported (Helander 
et al., 2013; Taljemark and Johansson, 2012). The subjective effects of these 4-
substituted tryptamines that are used at oral doses of 10-20 mg are reportedly similar 
to those of psilocybin and last 2-6 h. The receptor interaction profiles of 4-OH-DiPT 
and 4-OH-MET are unknown (Tittarelli et al., 2015).  
5-MeO-AMT and 5-MeO-MiPT (user names: “Alpha” and “Moxy,” respectively) 
are 5-methoxy-substituted tryptamines that exert psychoactive effects at oral doses 
of 2-6 mg (Greene, 2013; Shulgin and Shulgin, 1997; Tittarelli et al., 2015). The 
clinical effects of 5-MeO-AMT reportedly last up to 18 h, and severe toxicity has been 
associated with this substance (Tittarelli et al., 2015). 5-MeO-AMT is a potent 5-HT2A 
receptor ligand and agonist with some selectivity for the 5-HT2A receptor over the 5-
HT1 receptor (Gatch et al., 2011; Glennon et al., 1990; Tomaszewski et al., 1992). 
Data on other receptor interactions are lacking. 5-MeO-AMT has also been shown to 
act as a substrate releaser at rat monoamine transporters and the human SERT 
(Gatch et al., 2011). A recent study showed that 5-MeO-MiPT stimulated 5-HT2 
receptors but did not interact with rat monoamine transporters (Blough et al., 2014), 
in contrast to its close analog 5-methoxy-diisopropyltryptamine (5-MeO-DiPT), which 
acted at the SERT (Blough et al., 2014; Sogawa et al., 2007). In contrast, a previous 
study found that both 5-MeO-MiPT and 5-MeO-DiPT were inhibitors of the rat SERT 
and NET (Nagai et al., 2007). Thus, conflicting data have been reported, and more 
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comprehensive profiles of 5-MeO-AMT and 5-MeO-MiPT at human transporters and 
other receptors are needed. 
Psilocin (the active metabolite of psilocybin that is contained in magic 
mushrooms) and DMT (contained in ayahuasca) are classic tryptamines that 
continue to be used recreationally (Winstock et al., 2014). Psilocin and DMT are 5-
HT2A receptor agonists and SERT inhibitors (Blough et al., 2014; Cozzi et al., 2009). 
DMT also releases 5-HT (Blough et al., 2014). Less is known about interactions with 
other receptors. Clinically, psilocybin has been extensively studied in laboratory 
studies in healthy subjects and substance-assisted psychotherapy in patients 
(Carhart-Harris et al., 2013; Griffiths et al., 2006; Grob et al., 2011; Hasler et al., 
2004). Similarly, the acute psychotropic effects of DMT have been described in 
controlled studies in humans (Dos Santos et al., 2011; Gouzoulis-Mayfrank et al., 
2005; Strassman and Qualls, 1994; Strassman et al., 1994; Winstock et al., 2014). 
Furthermore, the prototypical hallucinogen LSD has received renewed attention in 
psychiatric research (Dolder et al., 2015; Geyer, 2015; Kupferschmidt, 2014; Schmid 
et al., 2015) and as an adjunct to psychotherapy to treat anxiety (Gasser et al., 
2014). Thus, the classic hallucinogens psilocin, DMT, and LSD were also included in 
the present study to provide more up-to-date basic in vitro pharmacological data on 
these clinically important substances, including profiles at human receptors, and 
allow direct comparisons between these classic substances with novel tryptamines 
and other novel psychoactive substances within the same assays (Liechti, 2015; 
Rickli et al., 2015a; Rickli et al., 2015b; Rickli et al., 2015c; Simmler et al., 2013; 
Simmler et al., 2016; Simmler et al., 2014a; Simmler et al., 2014b).  
 
 
2. Experimental procedures 
2.1. Drugs 
Psilocin, LSD, DMT, mescaline, and MDMA were obtained from Lipomed 
(Arlesheim, Switzerland). DiPT, 4-OH DiPT, 4-OH MET, 5-MeO AMT, and 5-MeO 
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MiPT were obtained from Cayman Chemicals (Adipogen, Switzerland). The 
compounds were used as racemates. The purity of the compounds was at least 98%. 
The radiolabeled chemicals [3H]NE and [3H]DA were purchased from Perkin-Elmer 
(Schwerzenbach, Switzerland), and [3H]5-HT was obtained from Anawa (Zürich, 
Switzerland). The data on LSD and mescaline were previously published but 
included herein for comparison because the data were obtained at the same time 
and by the same researcher using the same cell batches and assays as for the other 
compounds that are newly presented herein. 
 
2.2. Radioligand receptor and transporter binding assays 
 The radioligand binding assays were performed as described previously 
(Simmler et al., 2013). Briefly, membrane preparations of human embryonic kidney 
(HEK) 293 cells (Invitrogen, Zug, Switzerland) that overexpress the respective 
transporters (Tatsumi et al., 1997) or receptors (human genes, with the exception of 
rat and mouse genes for TAAR1; (Revel et al., 2011) were incubated with the 
radiolabeled selective ligands at concentrations equal to Kd, and ligand displacement 
by the compounds was measured. Specific binding of the radioligand to the target 
receptor was defined as the difference between the total binding and nonspecific 
binding that was determined in the presence of selected competitors in excess. The 
following radioligands and competitors, respectively, were used: N-methyl-[3H]-
nisoxetine and indatraline (NET), [3H]citalopram and indatraline (SERT), 
[3H]WIN35,428 and indatraline (DAT), [3H]8-hydroxy-2-(di-n-propylamine)tetralin and 
indatraline (5-HT1A receptor), [
3H]ketanserin and spiperone (5-HT2A receptor), 
[3H]mesulgerine and mianserin (5-HT2C receptor), [
3H]prazosin and risperidone 
(adrenergic α1 receptor), [
3H]rauwolscine and phentolamine (adrenergic α2 receptor), 
[3H]SCH 23390 and butaclamol (D1 receptor), [
3H]spiperone and spiperone (D2 and 
D3 receptors), [
3H]pyrilamine and clozapine (histaminergic H1 receptor), and 
[3H]RO5166017 and RO5166017 (TAAR1). IC50 values were determined by 
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calculating nonlinear regression curves for a one-site model using three to five 
independent 10-point concentration-response curves for each compound. Ki (affinity) 
values, which correspond to the dissociation constants, were determined using the 
Cheng-Prusoff equation. 
 
2.3. Activity at the serotonin 5-HT2A receptor 
 Human 5-HT2A receptor-expressing mouse embryonic fibroblasts (NIH-3T3 
cells) were incubated in HEPES-Hank’s Balanced Salt Solution (HBSS) buffer 
(70,000 cells/100 µl) for 1 h at 37ºC in 96-well poly-D-lysine-coated plates. To each 
well 100 µl of dye solution (fluorescence imaging plate reader [FLIPR] calcium 5 
assay kit; Molecular Devices, Sunnyvale, CA, USA) was added, and the plates were 
incubated for 1 h at 37°C. The plates were then placed in a FLIPR, and 25 µl of the 
test substances diluted in HEPES-HBSS buffer that contained 250 mM probenicid 
was added online. The increase in fluorescence was then measured. EC50 values 
were derived from the concentration-response curves using nonlinear regression. 
Efficacy (maximal activity) is expressed relative to the activity of 5-HT, which was 
used as a control set to 100%. 
 
2.4. Activity at the serotonin 5-HT2B receptor 
 Human 5-HT2B receptor-expressing HEK293 cells were incubated in growth 
medium (Dulbecco’s Modified Eagle Medium [DMEM] high glucose [Invitrogen, Zug, 
Switzerland], 10 ml/L PenStrep [Gibco, Life Technologies, Zug, Switzerland], 10% 
fetal calf serum [non-dialysed, heat-inactivated], and 250 mg/l geneticin) at a density 
of 50,000 cells/well at 37ºC in 96-well poly-D-lysine-coated plates overnight. The next 
day, the growth medium was removed by snap inversion, and 100 µl of the calcium 
indicator Fluo-4 solution (Molecular Probes, Eugene, OR, USA) was added to each 
well. The plates were incubated for 45 min at 31C. The Fluo-4 solution was removed 
by snap inversion, and 100 µl of Fluo-4 solution was added a second time. The cells 
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were then incubated for another 45 min at 31C. Immediately before testing, the cells 
were washed with HBSS (Gibco) and 20 mM HEPES (assay buffer; Gibco) using an 
EMBLA cell washer, and 100 µl assay buffer was added. The plates were placed in a 
FLIPR, and 25 µl of the test substances diluted in assay buffer was added online. 
The increase in fluorescence was then measured. EC50 values were derived from the 
concentration-response curves using nonlinear regression. Efficacy (maximal 
activity) is expressed relative to the activity of 5-HT, which was used as a control set 
to 100%. 
 
2.5. Monoamine uptake transporter inhibition 
We assessed inhibition of the human NET, DAT, and SERT in transfected 
HEK293 cells that stably expressed the monoamine transporters as previously 
specified (Hysek et al., 2012). Briefly, cells were suspended in uptake buffer, treated 
with different concentrations of the test substances, and incubated for 10 min at room 
temperature. The corresponding radiolabeled monoamine, [3H]NE, [3H]DA, or [3H]5-
HT was then added at a final concentration of 5 nM at room temperature. After 10 
min, the cells were centrifuged through silicone oil to separate them from the uptake 
buffer. The tubes were then frozen in liquid nitrogen immediately after centrifugation. 
The cell pellets were then lysed, and scintillation fluid was added. Radioactivity was 
measured with a beta counter, and nonspecific uptake in the presence of specific 
transporter inhibitors (10 µM nisoxetine for NET cells, 10 µM mazindol for DAT cells, 
and 10 µM fluoxetine for SERT cells) was determined for each experiment. This 
nonspecific uptake was subtracted from the total counts to yield specific uptake 
(100%). The data were fitted with nonlinear regression to variable-slope sigmoidal 
dose-response curves, and IC50 values were calculated using Prism software 
(GraphPad, San Diego, CA, USA). MDMA was included for comparison.  
 
2.6. Transporter-mediated monoamine release 
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We investigated the effects of a single high dose (100 µM) of the test 
compounds on transporter-mediated NE, DA, and 5-HT efflux in HEK293 cells that 
stably overexpressed the respective human monoamine transporter as previously 
described (Simmler et al., 2013). Briefly, adherent cells were incubated with the 
respective radiolabeled monoamine (10 nM [3H]NE and 10 µM unlabeled NE, 10 nM 
[3H]DA and 1 µM unlabeled DA, and 10 nM [3H]5-HT) for 20 min at 37°C. The cells 
were then washed twice with KHB buffer, and 1 ml of buffer that contained the test 
compound was added (100 µM final concentration). [3H]5-HT and [3H]DA release 
was stopped after 15 min, and [3H]NE release was stopped after 45 min by washing 
with ice-cold buffer. Release was quantified by measuring the radioactivity that 
remained in the cells. Nonspecific “pseudo-efflux,” which arises from nonspecific 
substrate release and subsequent reuptake inhibition (Scholze et al., 2000), was 
assessed for each experiment using the transporter inhibitors nisoxetine (NET cells), 
citalopram (SERT cells), and mazindol (DAT cells) at 10 µM as negative controls. 
Analysis of variance (ANOVA) followed by Dunnett’s test was used to compare 
compound-induced release with the negative controls. Substances that exhibited 
significant higher outflow than the controls were considered monoamine releasers. 
 
2.7. Cytotoxicity 
 To confirm cell integrity during the pharmacological assays, cytotoxicity was 
assessed using the ToxiLight bioassay (Lonza, Basel, Switzerland) according to the 
manufacturer’s instructions. The assay quantitatively measures the release of 
adenylate kinase from damaged cells, providing a highly sensitive method of 
measuring cytolysis (Crouch et al., 1993). Cells that were grown in 96-well plates 
were exposed to the compounds at a high concentration of 100 µM. All of the test 
conditions contained 0.1% (v:v) dimethylsulfoxide, which is nontoxic at this 
concentration and was also used as a negative control. Triton X-100 (0.1%, Sigma-
Aldrich, Buchs, Switzerland) lyses cells and was used as a positive control. After 4 h 
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incubation at 37C, 10 µl of the supernatant per well was removed and combined 
with 50 µl of ToxiLight reagent, and luminescence was recorded using a Tecan 
Infinite 200 Pro plate reader (Tecan, Männedorf, Switzerland). 
 
3. Results 
3.1. Interactions with serotonin receptors 
Table 1 presents binding to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors 
and activation potency and efficacy at 5-HT2A and 5-HT2B receptors. All of the tested 
hallucinogens bound to or activated 5-HT receptors mostly at submicromolar 
concentrations. LSD was the compound that most potently bound to the 5-HT2A 
receptor, which is considered the primary target of hallucinogenic compounds. 
Binding affinity to the 5-HT2A receptor was lower for all of the tryptamines, including 
psilocin and DMT, compared with LSD. Mescaline was the least potent. Among all of 
the substances tested in the present study, the Ki values for 5-HT2A receptor binding 
were not associated with the EC50 values for 5-HT2A receptor activation (Spearman 
rank correlation, Rs = 0.4, p > 0.1, n = 10). Similarly, 5-HT2A receptor binding (Ki 
values) was not correlated with receptor activation when only the tryptamines were 
analyzed (Rs = 0.4, p > 0.1, n = 7). For the tryptamines, 5-HT2A receptor binding 
affinity (Rs = 0.9, p < 0.05, n = 7) but not 5-HT2A receptor activation potency (Rs = 0.6, 
n = 7, p > 0.1) was significantly correlated with the estimated mean doses that 
produced hallucinogenic subjective effects (Table 1; (Tittarelli et al., 2015).   
5-HT2A receptor activation potency was highest for 5-MeO-AMT, followed by 
all of the tryptamines, for which 5-HT2A receptor activation potency was higher than 
the binding affinity. In contrast, for LSD, psilocin, and mescaline, 5-HT2A receptor 
activation potency was low compared with their high binding affinity. As a result, all of 
the tryptamines, including DMT but with the exception of psilocin, were more potent 
agonists at the 5-HT2A receptor than LSD in the assay that was used in the present 
study. LSD and psilocin were 5-HT2A receptor partial agonists, with 28% and 16% 
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activation efficacy, respectively, whereas all of the other compounds presented 
higher 5-HT2A receptor activation efficacies (up to > 80% for DiPT and 5-MeO-MiPT). 
Generally, the hallucinogens bound more potently to the 5-HT2A receptor than to the 
5-HT2C receptor. However, 5-HT2A over 5-HT2C receptor binding selectivity was low 
(binding ratios < 10) for all of the compounds. LSD and most of the other drugs were 
relatively equally potent at 5-HT2A and 5-HT1A receptors, and LSD was the only 
compound to exhibit 5-HT1A receptor affinity at 1-digit nanomolar concentrations. 
Only 5-MeO-AMT and 4-OH-DiPT activated the 5-HT2B receptor at submicromolar 
concentrations. 
 
3.2. Binding to monoamine receptors and transporters 
Table 2 shows the binding affinities to monoamine transporters and 
receptors. Binding to transporters was generally weak, with the exception of DiPT 
and 4-OH-MET, which exhibited submicromolar binding affinity to the SERT. LSD 
was the only compound that bound to α1-adrenergic receptors with submicromolar 
affinity. DMT also exhibited moderate binding to α1-adrenergic receptors (Ki = 1.3 
µM). LSD bound to α2-adrenergic receptors at submicromolar concentrations. Only 
LSD showed affinity to dopaminergic D1-3 receptors and exhibited submicromolar 
affinity to TAAR1rat. 
 
3.3. Monoamine uptake transporter inhibition 
Monoamine uptake inhibition for at least one transporter was found for all of 
the substances, with the exception of mescaline and LSD (Table 3). Psilocin, DMT, 
DiPT, and 4-OH-DiPT inhibited the SERT, with IC50 values in the low micromolar 
range, similar to MDMA. Additionally, psilocin, DMT, DiPT, and 4-OH-MET inhibited 
NET but with lower potency than MDMA. All of the substances were no or very weak 
DAT inhibitors, in contrast to MDMA (Table 3). 
 
  13 
3.4. Transporter-mediated monoamine release by tryptamines 
Monoamine release was assessed only for tryptamines because LSD and 
mescaline did not interact with the monoamine transporters in the transporter 
inhibition assay and were shown not to release monoamines in previous studies 
(Rickli et al., 2015c). DMT released 5-HT, and 5-MeO-AMT released 5-HT and DA, 
whereas none of the other substances acted as substrate releasers (Fig. 2). 
 
3.5. Cytotoxicity 
 None of the substances produced cytotoxicity after 4 h incubation in the 
adenylate-kinase release assay, indicating no cell damage. 
 
4. Discussion 
All of the tryptamines that were tested in the present study bound to and 
activated the 5-HT2A receptor, extending previous in vitro studies on this group of 
hallucinogens (Blough et al., 2014; Gatch et al., 2011; McKenna et al., 1990; Nichols 
et al., 2015; Repke et al., 1985; Shulgin and Carter, 1980). None of the tryptamines 
was very selective for the 5-HT2A receptor over other 5-HT1A receptor. 
The present study confirms and extends previous characterizations of 
tryptamines. DiPT was a full 5-HT2A receptor agonist (101% efficacy) in the present 
study, consistent with high efficacy in an inositol-1-phosphate formation assay (82%; 
Gatch et al., 2011) and a calcium mobilization assay (110%; Blough et al., 2014). 
DiPT inhibited the human SERT (IC50 = 0.9 µM) as shown in studies that utilized rat 
brain synaptosomes (Blough et al., 2014) and human cells (Gatch et al., 2011) at a 
potency similar to MDMA (IC50 = 1.4 µM). DiPT also weakly inhibited the NET (IC50 = 
9.9 µM) as previously shown for the human transporter (Blough et al., 2014) but not 
rat transporter (Gatch et al., 2011). DiPT activity at the DAT was low (IC50 > 10 µM) 
and even weaker than previously reported (Blough et al., 2014; Gatch et al., 2011). 
Confirming a previous study that used rat synaptosomes (Blough et al., 2014), DiPT 
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did not release monoamines via the human transporter in the present study. Our new 
data on 4-OH-DiPT and 4-OH-MET showed that these 4-ring-substituted compounds 
were 5-HT2A receptor partial agonists, SERT inhibitors, and weak NET inhibitors, 
exhibiting a similar profile to psilocin and consistent with their reportedly common 
clinical effects (Tittarelli et al., 2015). 5-MeO-AMT was the most potent 5-HT2A 
receptor ligand and agonist among the tryptamines that were evaluated in the 
present study and previous studies (Gatch et al., 2011). 5-MeO-AMT was a very 
weak monoamine transporter inhibitor, especially considering its much higher 
potency at the 5-HT2A receptor. 5-MeO-AMT also induced the transporter-mediated 
release of DA and 5-HT as previously shown for the rat DAT and SERT (Nagai et al., 
2007) and human SERT (Gatch et al., 2011). 5-MeO-AMT did not directly interact 
with adrenergic receptors. Together with the low-potency interaction with 
catecholamine transporters, our data indicate that the reported cardiostimulant 
effects of 5-MeO-AMT (Repke et al., 1985; Tittarelli et al., 2015) likely depend on the 
relatively potent 5-HT2A receptor interactions rather than direct effects on the 
adrenergic systems, similar to hallucinogenic benzodifurans (Rickli et al., 2015b). 5-
MeO-MiPT was a near-full (83%) agonist at the 5-HT2A receptor, consistent with 
previous data (101%; Blough et al., 2014). 5-MeO-MiPT had no relevant action at the 
human monoamine transporters, consistent with recent data (Blough et al., 2014). 
Psilocin and DMT were agonists at the 5-HT2A receptor with low efficacy. 
Additionally, psilocin was a SERT inhibitor, and DMT was a dual SERT-NET inhibitor 
and 5-HT releaser as reported previously (Blough et al., 2014; Cozzi et al., 2009).  
Clear differences were found between the pharmacological profiles of the 
tryptamines and classic and well-studied hallucinogen LSD. First, LSD more potently 
bound to 5-HT2A receptors compared with all of the tryptamines. Second, LSD was 
absolutely and in most cases also relatively more potent than all of the tryptamines at 
the 5-HT1 receptor, which may moderate the in vivo effects of hallucinogens 
(Halberstadt et al., 2011; Krebs-Thomson et al., 2006; Sipes and Geyer, 1994; 
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Strassman, 1996). Third, all of the novel tryptamines were full agonists at the 5-HT2A 
receptor or presented > 50% activation efficacy, whereas LSD, DMT, and psilocin 
were partial agonists with < 40% activation efficacy. Fourth, LSD bound to adrenergic 
and dopaminergic receptors at submicromolar concentrations, which was not the 
case for any of the other substances. Dopamine D2 receptors may therefore 
contribute to the effects of LSD (Giacomelli et al., 1998; Marona-Lewicka et al., 2005) 
but are not or less involved in the action of tryptamines. Finally, all of the tryptamines 
inhibited the SERT in the case of DiPT at submicromolar concentrations, similar to 
MDMA. Additionally, NET inhibition was observed for DMT and DiPT, and 
transporter-mediated 5-HT release was observed for DMT and 5-MeO-AMT. In 
contrast, LSD and mescaline did not interact with the monoamine transporters. 
Consistent with our findings, DMT was previously shown to release 5-HT from 5-HT-
preloaded rat synaptosomes (Blough et al., 2014), and DiPT and psilocin but not 5-
MeO-MiPT inhibited the rat SERT (Blough et al., 2014). DMT, DiPT, and 5-MeO-AMT 
have also been previously shown to inhibit the human SERT (Cozzi et al., 2009; 
Gatch et al., 2011), and 5-MeO-AMT released 5-HT through the human SERT, 
similar to our findings (Gatch et al., 2011). Altogether, the results indicate that activity 
at the SERT may contribute to the pharmacology of several tryptamines. This is most 
likely relevant for DiPT and 4-OH-DiPT where the SERT inhibition potency is in the 
range of the binding potency at the 5-HT2A receptor. It remains to be determined how 
interactions with SERT contribute to the effects of these tryptamines in vivo.    
The pharmacological profiles of psilocin and LSD are particularly interesting 
because both substances currently receive high interest as research tools and 
potential therapeutic substances in psychiatry (Geyer, 2015; Halberstadt, 2015; 
Kupferschmidt, 2014). Clinically, the acute effects of psilocybin last shorter than 
those of LSD but are qualitatively very similar (Passie et al., 2008). The present 
study showed that LSD was a more potent 5-HT2A receptor ligand compared with 
psilocin, consistent with its higher clinical potency (Schmid et al., 2015; Studerus et 
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al., 2011). At 5-HT receptors, both substances were 5-HT2A receptor partial agonists 
with low efficacy and low selectivity for the 5-HT2A receptor over the 5-HT1A or 5-HT2C 
receptor. LSD was also 10- to 100-fold more potent at α1- and α2-adrenergic and 
dopaminergic D1-3 receptors than psilocin in the present study. However, because 
psilocin (psilocybin) is used at approximately 100-fold higher doses than LSDthe 
profile was overall quite similar, with the exception that psilocin inhibited the SERT. 
Whether this is clinically relevant needs to be determined, and modern clinical 
studies that directly compare the effects of psilocybin and LSD are currently lacking. 
The affinity of hallucinogens at the 5-HT2A receptor but not at the 5-HT1A receptor 
has been shown to correlate with psychoactive potency in humans (Sadzot et al., 
1989; Titeler et al., 1988). The tryptamines that were tested in the present study all 
exhibited significantly lower affinity to the 5-HT2A receptor compared with LSD. 
Tryptamines can be expected to be psychoactive at higher doses than LSD. Indeed, 
LSD is psychoactive at oral doses of 0.05-0.1 mg (Passie et al., 2008), whereas the 
tryptamine with the highest 5-HT2A receptor binding affinity in the present study (5-
MeO-AMT) is psychoactive at 2-5 mg (Shulgin and Shulgin, 1997; Tittarelli et al., 
2015). The tryptamine with the lowest 5-HT2A receptor affinity, DiPT, is psychoactive 
at 20-100 mg (Shulgin and Carter, 1980; Tittarelli et al., 2015). For the seven 
tryptamines that were evaluated in the present study, we found a significant 
correlation between 5-HT2A receptor binding affinity and the estimated average doses 
at which the tryptamines are psychoactive in humans (Tittarelli et al., 2015) as 
previously shown for other hallucinogens (Sadzot et al., 1989; Titeler et al., 1988). In 
contrast, 5-HT2A receptor activation potency did not correlate with the human doses. 
Notably, 5-HT2A receptor activation potency did not reflect binding potency for the 
series of substances that were tested. Consistent within other hallucinogens, no clear 
correlation was found between binding affinity to the 5-HT2A receptor and its 
functional activation potency (Nichols et al., 2015). Importantly, 5-HT2A receptor 
activation is measured using various in vitro assays that reflect the activation of 
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different second messenger systems (Moya et al., 2007; Nichols, 2004), and these 
measures may apparently not reflect the mechanisms that mediate the subjective 
effects of these hallucinogens. 
Many psychoactive compounds bind to TAAR1 (Bunzow et al., 2001; Simmler et 
al., 2013; Simmler et al., 2016), a potential target for the treatment of addiction 
(Cotter et al., 2015; Jing and Li, 2015; Pei et al., 2015). Psilocin, DMT, 4-OH-MET, 
and 5-MeO-AMT had low-micromolar affinity to TAAR1rat. LSD and the hallucinogenic 
phenethylamines and benzofurans were shown to be more potent TAAR1 ligands 
(Rickli et al., 2015b; Rickli et al., 2015c). TAAR1 agonism was reported to reduce 
monoamine system stimulation and the stimulant properties of MDMA (Di Cara et al., 
2011). Thus, greater TAAR1 interactions may be linked to lower stimulant-type 
properties (Simmler et al., 2013; Simmler et al., 2014a; Simmler et al., 2014b). The 
relevance of TAAR1 binding to the subjective and reinforcing properties of 
tryptamines requires further study. 
As expected, we observed several structure-activity relationships. Among the 
tryptamines, 5-MeO-AMT exhibited the highest 5-HT2A receptor affinity and activation 
potency. The α-methylation and 5-methoxylation of tryptamines have both been 
shown to increase their potency. -Methyl-5-HT and fluoro-α-methyltryptamines were 
shown to be more potent than their non--methylated analogs in inducing 
hallucinogen-typical head-twitch responses in mice (Nakagawasai et al., 2004; 
Tadano et al., 1995). Similarly, the α-methylation of phenethylamines increased 5-
HT2A receptor stimulation efficacy and head-twitch responses (Moya et al., 2007). 
The 5-methoxylation of tryptamines has been shown to increase 5-HT2A receptor 
affinity and receptor activation potency for 5-MeO-DiPT vs. DiPT and for 5-MeO-
MiPT vs. MiPT (Blough et al., 2014; Rogawski and Aghajanian, 1981). In the present 
study, 4-hydroxylation also increased 5-HT2A receptor binding for psilocin vs. DMT 
and for 4-OH-DiPT vs. DiPT, consistent with previous studies (McKenna et al., 1990; 
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Repke et al., 1985; Rogawski and Aghajanian, 1981). N-substitutions are also known 
to alter the receptor interaction profiles of psychoactive tryptamines and 
phenethylamines (Braden et al., 2006; McKenna et al., 1990; Nichols et al., 2015; 
Repke et al., 1985; Rickli et al., 2015c). In our series, N,N-isopropylation, such as in 
DiPT, reduced binding affinity at 5-HT2 receptors compared with N,N-methylation, 
such as in DMT. In contrast, asymmetrical N-methyl-N-isopropyl substitutions 
(MiPTs) resulted in greater activity compared with symmetrical N-alkyl substitution 
(Repke et al., 1985). Importantly, N-benzyl-substitutions with an ortho-substituent on 
the benzyl group resulted in highly potent phenethylamines (NBOMes; Braden et al., 
2006; Rickli et al., 2015c), whereas N-benzyl-substitution with a meta-substituent on 
the benzyl group produced potent tryptamines (Nichols et al., 2015).  
The presents study has limitations. The in vitro mechanism of action helps to 
predict clinical effects. However, additional factors such as absorption, protein 
binding, brain penetration, and metabolism also play a role and need to be 
addressed in future studies. For example, LSD may exhibit better brain penetration 
than tryptamines (Passie et al., 2008).  
In conclusion, all of the tested tryptamines were partial or full 5-HT2A receptor 
agonists and mostly interacted with the 5-HT transporter, similar to MDMA. In 
contrast to LSD, the tryptamines exhibited no or only low-potency interactions with 
adrenergic and dopaminergic receptors. The in vitro pharmacological data indicate 
that these tryptamines exert both hallucinogenic and MDMA-like effects in humans. 
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Figure Legends 
 
Figure 1. Chemical structures of tryptamines, LSD, and mescaline.  
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Figure 2. Monoamine release induced by tryptamines. Monoamine release was 
induced by a high concentration of the test substances (100 µM) after preloading 
HEK293 cells that stably expressed NET, DAT, or SERT. Most of the tryptamines did 
not release monoamines. Only DMT released 5-HT, and 5-MeO-AMT released 5-HT 
and DA. MDMA was added as a positive control, which releases all monoamines. 
Transporter blockers were included as negative controls (open bars) that produce 
non-transporter-mediated “pseudo-efflux” (horizontal dashed line). Compounds that 
produced significantly more monoamine efflux (*p < 0.05, **p < 0.01, ***p < 0.001) 
compared with the respective non-releasing uptake inhibitors (nisoxetine, mazindol, 
or citalopram) were considered monoamine releasers. The data are expressed as 
the mean ± SEM of three to four independent experiments.
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Table 1. Serotonin receptor interactions 
                                 
  
  
5-HT1A   
5-HT2A  
5-HT2B   
5-HT2C     
  
  
 
      
 
    
 
  
 
  
  
receptor binding 
Ki ± SD [µM]  
receptor binding 
Ki ± SD [µM] 
activation 
potency EC50 ± 
SD [µM] 
activation 
efficacy % 
maximum ± SD 
 
activation 
potency EC50 ± 
SD [µM] 
activation 
efficacy % 
maximum ± SD 
 
receptor 
binding Ki ± SD 
[µM] 
 
psychoactive 
dose
b
 [mg] 
                        
 
  
              
Tryptamines 
            
 
Psilocin 0.123 ± 0.02 
 
0.049 ± 0.01 0.721 ± 0.55 16 ± 8 
 
> 20 
  
0.094 ± 0.009 
 
12 
 
DMT 0.075 ± 0.02 
 
0.237 ± 0.04 0.076 ± 0.03 40 ± 11 
 
3.4 ± 3.2 19 ± 6 
 
0.424 ± 0.15 
 
40 
 
DiPT 0.538 ± 0.05 
 
1.2 ± 0.3 0.240 ± 0.08 101 ± 2 
 
1.0 ± 0.2 103 ± 15 
 
6.5 ± 1.6 
 
75 
 
4-OH-DiPT 5.7 ± 0.9 
 
0.728 ± 0.07 0.093 ± 0.03 74 ± 14 
 
0.460 ± 0.36 55 ± 10 
 
2.8 ± 1.2 
 
18 
 
4-OH-MET 0.228 ± 0.06 
 
0.057 ± 0.01 0.037 ± 0.01 72 ± 11 
 
> 20 
  
0.141 ± 0.03 
 
15 
 
5-MeO-AMT 0.046 ± 0.005 
 
0.034 ± 0.01 0.002 ± 0.0002 60 ± 5 
 
0.004 ± 0.001 104 ± 19 
 
0.090 ± 0.03 
 
3 
 
5-MeO-MiPT 0.058 ± 0.01 
 
0.163 ± 0.03 0.023 ± 0.004 83 ± 7 
 
1.5 ± 0.9 12 ± 7 
 
1.3 ± 0.3 
 
5 
              
Ergoline 
            
 
LSD
a
 0.003 ± 0.0005 
 
0.004 ± 0.001 0.261 ± 0.15 28 ± 10 
 
12 ± 0.4 71 ± 31 
 
0.015 ± 0.003 
 
0.1 
              
Phenethylamine 
            
 
Mescaline
a
 4.6 ± 0.4 
 
6.3 ± 1.8 10 ± 1.8 56 ± 15 
 
> 20 
  
17 ± 2.0 
 
300 
                           
Values are Ki given as microM (mean± SD); 
a
Values have previously been published in Rickli et al. 2015c; 
b
Estimated average from Tittarelli et al. 2015; Passie et al. 2008, 
Nichols, 2004.  
  32 
Table 2. Monoamine transporter and receptor binding affinities.  
                          
  NET DAT SERT 1A A D1 D2 D3 H1 TAAR1rat
b
 TAAR1mouse
b
 
                          
Tryptamines 
           
 
Psilocin 13 ± 1.7 > 30 6.0 ± 0.3 6.7 ± 1.1 2.1 ± 0.01 > 14 3.7 ± 0.6 8.9 ± 0.8 1.6 ± 0.2 1.4 ± 0.2 17 ± 1.7 
 
DMT 6.5 ± 1.3 22 ± 3.9 6.0 ± 0.6 1.3 ± 0.2 2.1 ± 0.4 6.0 ± 0.9 3.0 ± 0.4 6.3 ± 2.1 0.22 ± 0.03 2.2 ± 0.2 3.3 ± 0.4 
 
DiPT 8.9 ± 0.9 4.1 ± 0.1 0.18 ± 0.02 > 12 3.6 ± 0.1 > 25 > 25 > 25 0.92 ± 0.36 > 15 > 15 
 
4-OH-DiPT 11 ± 2.8 > 26 1.8 ± 0.4 > 12 15 ± 1.6 > 25 > 25 > 25 9.8 ± 0.9 > 15 > 15 
 
4-OH-MET 13 ± 4.9 > 26 0.20 ± 0.06 9.7 ± 1.7 2.4 ± 0.2 > 25 4.0 ± 0.2 6.7 ± 2.0 0.82 ± 0.09 3.1 ± 0.2 12 ± 3.4 
 
5-MeO-AMT > 22 > 26 12 ± 1.1 > 12 11 ± 0.3 > 25 > 25 > 25 > 25 1.1 ± 0.2 4.8 ± 0.9 
 
5-MeO-MiPT > 22 > 26 3.3 ± 0.3 > 12 5.3 ± 0.3 > 25 > 25 > 25 3.9 ± 0.5 > 15 > 15 
             
Ergoline 
           
 
LSD
a
 > 30 > 30 > 30 0.67 ± 0.18 0.012 ± 0.002 0.31 ± 0.09 0.025 ± 0.0004 0.10 ± 0.01 1.1 ± 0.2 0.45 ± 0.05 10 ± 2.9 
             
Phenethylamines 
           
 
Mescaline
a
 > 30 > 30 > 30 > 15 1.4 ± 0.2 > 14 > 10 > 17 > 25 3.3 ± 0.5 11 ± 3.6 
                         
Values are Ki  given as microM (mean ± SD).  
a
Values have previously been published in Rickli et al. 2015c. 
b
Values have previously been published in Simmler et al. 2016.  
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Table 3. Monoamine transporter inhibition 
  
    NET DAT SERT 
    IC50 [µM] (95% CI) IC50 [µM] (95% CI) IC50 [µM] (95% CI) 
Tryptamines 
   
 
Psilocin 14 (10-19) >100 3.9 (3.1-4.8) 
 
DMT 3.9 (2.8-5.3) 52 (37-72) 3.1 (2.4-4.0) 
 
DiPT 9.9 (7.4-13) 35 (28-45) 0.9 (0.7-1.2) 
 
4-OH-DiPT 46 (33-62) >100 2.4 (1.7-3.4) 
 
4-OH-MET 11 (8-14) >100 9.0 (6.7-12) 
 
5-MeO-AMT 78 (67-90) 43 (35-53) 17 (11-24) 
 
5-MeO-MiPT 84 (65-109) >100 22 (17-28) 
     
Ergoline 
   
 
LSD
a
 >100 >100 >100 
     
Phenethylamines 
   
 
Mescaline
a
 >100 >100 >100 
 
MDMA 0.20 (0.11-0.36) 14 (8.4-23) 1.4 (1.0-2.0) 
         
Values are means of three to four independent experiments and 95% confidence intervals 
(CI).  
a
Values have previously been published in Rickli et al. 2015c  
 
